litlas
Log inCreate account

George W. Sledge

Active 1986–2026

Also published as
George W Sledge
160
Papers
38,640
Citations
92
h-index
151
i10-index

Citations

Citations per year for George W. Sledge1971: 1 citations1980: 1 citations1981: 1 citations1987: 2 citations1988: 4 citations1989: 5 citations1990: 4 citations1991: 3 citations1992: 10 citations1993: 5 citations1994: 4 citations1995: 7 citations1996: 8 citations1997: 15 citations1998: 15 citations1999: 42 citations2000: 42 citations2001: 49 citations2002: 103 citations2003: 116 citations2004: 120 citations2005: 142 citations2006: 140 citations2007: 140 citations2008: 157 citations2009: 221 citations2010: 254 citations2011: 245 citations2012: 257 citations2013: 265 citations2014: 210 citations2015: 296 citations2016: 342 citations2017: 349 citations2018: 384 citations2019: 1,277 citations2020: 1,553 citations2021: 1,452 citations2022: 1,109 citations2023: 821 citations2024: 1,181 citations2025: 556 citations2026: 30 citations1972–1979: no citations, so these years are not shown1982–1986: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 4,569 citing papers, 26.8% of this breakdownChina: 1,420 citing papers, 8.3% of this breakdownItaly: 1,002 citing papers, 5.9% of this breakdownUnited Kingdom: 907 citing papers, 5.3% of this breakdownGermany: 792 citing papers, 4.7% of this breakdownFrance: 664 citing papers, 3.9% of this breakdownCanada: 657 citing papers, 3.9% of this breakdownSpain: 611 citing papers, 3.6% of this breakdownAustralia: 450 citing papers, 2.6% of this breakdownJapan: 450 citing papers, 2.6% of this breakdownSwitzerland: 431 citing papers, 2.5% of this breakdownBelgium: 423 citing papers, 2.5% of this breakdown
0%26.8%Other 27.4%

Institutions

Fields

  • Medicine52%
  • Biochemistry, Genetics and Molecular Biology38.9%
  • Immunology and Microbiology2.4%
  • Computer Science1.6%
  • Engineering1%
  • Materials Science0.8%
  • Other3.3%

Topics

  • Breast Cancer Treatment Studies7.8%
  • HER2/EGFR in Cancer Research5.6%
  • Advanced Breast Cancer Therapies5.6%
  • Cancer Genomics and Diagnostics4.6%
  • Cancer Treatment and Pharmacology3.5%
  • Cancer Immunotherapy and Biomarkers2.6%
  • Other70.3%

Coauthors

All papers

Open in search
  1. Liquid biopsy enters the clinic — implementation issues and future challenges

    Authors: Michail Ignatiadis, George W. Sledge, Stefanie S. Jeffrey - Nature Reviews Clinical Oncology 2021 cited by 1,160

  2. Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer

    Authors: Joseph A. Sparano, Robert J. Gray, Della Makower, Kathleen I. Pritchard, Kathy S. Albain, Daniel F. Hayes, Charles E. Geyer, Elizabeth Claire Dees, Matthew P. Goetz, John A. Olson, Tracy Lively, Sunil Badve, Thomas J. Saphner, Lynne I. Wagner, Timothy J. Whelan, Matthew J. Ellis, Soonmyung Paik, William C. Wood, Peter M. Ravdin, Maccon Keane, Henry Gómez, Pavan S. Reddy, Timothy F. Goggins, Ingrid A. Mayer, Adam Brufsky, Deborah Toppmeyer, Virginia Kaklamani, Jeffrey L. Berenberg, Jeffrey S. Abrams, George W. Sledge - New England Journal of Medicine 2018 cited by 2,369

  3. MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy

    Authors: George W. Sledge, Masakazu Toi, Patrick Neven, Joohyuk Sohn, Kenichi Inoue, Xavier Pivot, Olga Burdaeva, Meena Okera, Norikazu Masuda, Peter A. Kaufman, Han Koh, Eva‐Maria Grischke, Martin Frenzel, Yong Lin, Susana Barriga, Ian C. P. Smith, Nawel Bourayou, Antonio Llombart‐Cussac - Journal of Clinical Oncology 2017 cited by 1,656

  4. 3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)

    Authors: Fátima Cardoso, A. Costa, Elżbieta Senkus, Matti Aapro, Fabrice André, Carlos H. Barrios, Jonas Bergh, G.S. Bhattacharyya, Laura Biganzoli, Maria João Cardoso, L. Carey, D. Corneliussen-James, Giuseppe Curigliano, Véronique Dièras, N. El Saghir, Alexandru Eniu, Lesley Fallowfield, D. Fenech, Prudence A. Francis, Karen A. Gelmon, Alessandra Gennari, Nadia Harbeck, Clifford A. Hudis, Bella Kaufman, Ian E. Krop, Musa Mayer, Hanneke Meijer, Shirley Mertz, Shinji Ohno, Olivia Pagani, Efthymios Papadopoulos, Fedro A. Peccatori, Frédérique Penault‐Llorca, Martine Piccart, Jean‐Yves Pierga, Hope S. Rugo, Lillie D. Shockney, George W. Sledge, Sandra M. Swain, Christoph Thomssen, Andrew Tutt, Daniel Vorobiof, Binghe Xu, Larry Norton, Eric P. Winer - Annals of Oncology 2016 cited by 2,062

  5. The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2

    Authors: George W. Sledge, Masakazu Toi, Patrick Neven, Joohyuk Sohn, Kenichi Inoue, Xavier Pivot, Olga Burdaeva, Meena Okera, Norikazu Masuda, Peter A. Kaufman, Han Koh, Eva‐Maria Grischke, PierFranco Conte, Yi Lu, Susana Barriga, Karla Hurt, Martin Frenzel, Stephen Johnston, Antonio Llombart‐Cussac - JAMA Oncology 2019 cited by 987

  6. Integrated digital error suppression for improved detection of circulating tumor DNA

    Authors: Aaron M. Newman, Alexander F. Lovejoy, Daniel M. Klass, David M. Kurtz, Jacob J. Chabon, Florian Scherer, Henning Stehr, Chih Long Liu, Scott V. Bratman, Carmen Say, Li Zhou, Justin N. Carter, Robert B. West, George W. Sledge, Joseph B. Shrager, Billy W. Loo, Joel W. Neal, Heather A. Wakelee, Maximilian Diehn, Ash A. Alizadeh - Nature Biotechnology 2016 cited by 1,144

  7. Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancers From Two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199

    Authors: Sylvia Adams, Robert J. Gray, Sandra Demaria, Lori J. Goldstein, Edith A. Perez, Lawrence N. Shulman, Silvana Martino, Molin Wang, Vicky Jones, Thomas J. Saphner, Antonio C. Wolff, William C. Wood, Nancy E. Davidson, George W. Sledge, Joseph A. Sparano, Sunil Badve - Journal of Clinical Oncology 2014 cited by 1,333

  8. Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer

    Authors: Joseph A. Sparano, Robert J. Gray, Peter M. Ravdin, Della Makower, Kathleen I. Pritchard, Kathy S. Albain, Daniel F. Hayes, Charles E. Geyer, Elizabeth Claire Dees, Matthew P. Goetz, John A. Olson, Tracy Lively, Sunil Badve, Thomas J. Saphner, Lynne I. Wagner, Timothy J. Whelan, Matthew J. Ellis, Soonmyung Paik, William C. Wood, Maccon Keane, Henry Gómez, Pavan S. Reddy, Timothy F. Goggins, Ingrid A. Mayer, Adam Brufsky, Deborah Toppmeyer, Virginia Kaklamani, Jeffrey L. Berenberg, Jeffrey S. Abrams, George W. Sledge - New England Journal of Medicine 2019 cited by 555

  9. Prospective Validation of a 21-Gene Expression Assay in Breast Cancer

    Authors: Joseph A. Sparano, Robert J. Gray, Della Makower, Kathleen I. Pritchard, Kathy S. Albain, Daniel F. Hayes, Charles E. Geyer, Elizabeth Claire Dees, Edith A. Perez, John A. Olson, JoAnne Zujewski, Tracy Lively, Sunil Badve, Thomas J. Saphner, Lynne I. Wagner, Timothy J. Whelan, Matthew J. Ellis, Soonmyung Paik, William C. Wood, Peter M. Ravdin, Maccon Keane, Henry Gómez, Pavan S. Reddy, Timothy F. Goggins, Ingrid A. Mayer, Adam Brufsky, Deborah Toppmeyer, Virginia Kaklamani, James N. Atkins, Jeffrey L. Berenberg, George W. Sledge - New England Journal of Medicine 2015 cited by 1,439

  10. 6th and 7th International consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7)

    Authors: Fátima Cardoso, Shani Paluch–Shimon, Eva Schumacher-Wulf, Leonor Vasconcelos de Matos, Karen A. Gelmon, Matti Aapro, Jyoti Bajpai, Carlos H. Barrios, Jonas Bergh, Elizabeth Bergsten-Nordström, Laura Biganzoli, Maria João Cardoso, Lisa A. Carey, Mariana Chávez‐MacGregor, Runcie C.W. Chidebe, Javier Cortés, Giuseppe Curigliano, Rebecca Dent, Nagi S. El Saghir, Alexandru Eniu, Lesley Fallowfield, Prudence A. Francis, Sandra X. Franco Millan, Jenny Gilchrist, Joseph Gligorov, William J. Gradishar, Renate Haidinger, Nadia Harbeck, Xichun Hu, Ranjit Kaur, Belinda E. Kiely, Sungbae Kim, Smruti Koppikar, Marion Kuper‐Hommel, Frédéric Lecouvet, Ginny Mason, Shirley Mertz, Volkmar Müller, Claire Myerson, Silvia P. Neciosup, Birgitte Vrou Offersen, Shinji Ohno, Olivia Pagani, Ann H. Partridge, Frédérique Penault‐Llorca, Aleix Prat, Hope S. Rugo, Elżbieta Senkus, George W. Sledge, Sandra M. Swain, Christoph Thomssen, Daniel Vorobiof, Peter Vuylsteke, Theresa Wiseman, Binghe Xu, Alberto Costa, Larry Norton, Eric P. Winer - The Breast 2024 cited by 197

  11. Clinical Significance of PIK3CA and ESR1 Mutations in Circulating Tumor DNA: Analysis from the MONARCH 2 Study of Abemaciclib plus Fulvestrant

    Authors: Sara M. Tolaney, Masakazu Toi, Patrick Neven, Joohyuk Sohn, Eva-Maria Grischke, Antonio Llombart-Cussac, Hatem Soliman, Hong Wang, Sameera Wijayawardana, Valerie M. Jansen, Lacey M. Litchfield, George W. Sledge - Clinical Cancer Research 2022 cited by 105

  12. Trastuzumab Plus Adjuvant Chemotherapy for Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Planned Joint Analysis of Overall Survival From NSABP B-31 and NCCTG N9831

    Authors: Edith A. Perez, Edward H. Romond, Vera J. Suman, Jong‐Hyeon Jeong, George W. Sledge, Charles E. Geyer, Silvana Martino, Priya Rastogi, Julie R. Gralow, Sandra M. Swain, Eric P. Winer, Gerardo Colón‐Otero, Nancy E. Davidson, E. Mamounas, Jo Anne Zujewski, Norman Wolmark - Journal of Clinical Oncology 2014 cited by 998

  13. Weekly Paclitaxel in the Adjuvant Treatment of Breast Cancer

    Authors: Joseph A. Sparano, Molin Wang, Silvana Martino, Vicky Jones, Edith A. Perez, Tom Saphner, Antonio C. Wolff, George W. Sledge, William C. Wood, Nancy E. Davidson - New England Journal of Medicine 2008 cited by 1,029

  14. Association of Circulating Tumor Cells With Late Recurrence of Estrogen Receptor–Positive Breast Cancer

    Authors: Joseph A. Sparano, Anne O’Neill, Katherine Alpaugh, Antonio C. Wolff, Donald W. Northfelt, Chau T. Dang, George W. Sledge, Kathy D. Miller - JAMA Oncology 2018 cited by 199

  15. Change in Survival in Metastatic Breast Cancer with Treatment Advances: Meta-Analysis and Systematic Review

    Authors: Jennifer L. Caswell‐Jin, Sylvia K. Plevritis, Lü Tian, Christopher J. Cadham, Cong Xu, Natasha K. Stout, George W. Sledge, Jeanne S. Mandelblatt, Allison W. Kurian - JNCI Cancer Spectrum 2018 cited by 328

  16. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial

    Authors: Kathy S. Albain, William E. Barlow, Steven Shak, Gabriel N. Hortobágyi, Robert B. Livingston, I‐Tien Yeh, Peter M. Ravdin, Roberto Bugarini, Frederick L. Baehner, Nancy E. Davidson, George W. Sledge, Eric P. Winer, Clifford A. Hudis, James N. Ingle, Edith A. Perez, Kathleen I. Pritchard, Lois E. Shepherd, Julie R. Gralow, Carl Yoshizawa, D. Craig Allred, C. Kent Osborne, Daniel F. Hayes - The Lancet Oncology 2009 cited by 1,405

  17. Wnt signaling in triple negative breast cancer is associated with metastasis

    Authors: Nandini Dey, Benjamin G. Barwick, Carlos S. Moreno, Maja Ordanic-Kodani, Zhengjia Chen, Gabriella Oprea‐Ilies, Weining Tang, Charles Catzavelos, Kimberly F. Kerstann, George W. Sledge, Mark Abramovitz, Mark Bouzyk, Pradip De, Brian Leyland‐Jones - BMC Cancer 2013 cited by 251

  18. Long-Term Follow-Up of the E1199 Phase III Trial Evaluating the Role of Taxane and Schedule in Operable Breast Cancer

    Authors: Joseph A. Sparano, Fengmin Zhao, Silvana Martino, Jennifer A. Ligibel, Edith A. Perez, Tom Saphner, Antonio C. Wolff, George W. Sledge, William C. Wood, Nancy E. Davidson - Journal of Clinical Oncology 2015 cited by 223

  19. A combination of distribution- and anchor-based approaches determined minimally important differences (MIDs) for four endpoints in a breast cancer scale

    Authors: David T. Eton, David Cella, Kathleen J. Yost, Susan E. Yount, Amy H. Peterman, Donna Neuberg, George W. Sledge, William C. Wood - Journal of Clinical Epidemiology 2004 cited by 391

  20. Past, Present, and Future Challenges in Breast Cancer Treatment

    Authors: George W. Sledge, Eleftherios P. Mamounas, Gabriel N. Hortobágyi, Harold J. Burstein, Pamela J. Goodwin, Antonio C. Wolff - Journal of Clinical Oncology 2014 cited by 275

  21. Early Local Therapy for the Primary Site in De Novo Stage IV Breast Cancer: Results of a Randomized Clinical Trial (E2108)

    Authors: Seema A. Khan, Fengmin Zhao, Lori J. Goldstein, David Cella, Mark Basik, Mehra Golshan, Thomas B. Julian, Barbara A. Pockaj, Christine A. Lee, Wajeeha Razaq, Joseph A. Sparano, Gildy V. Babiera, Irene A. Dy, Sarika Jain, Paula Silverman, Carla S. Fisher, Amye J. Tevaarwerk, Lynne I. Wagner, George W. Sledge - Journal of Clinical Oncology 2022 cited by 178

  22. Race, Ethnicity, and Clinical Outcomes in Hormone Receptor-Positive, HER2-Negative, Node-Negative Breast Cancer in the Randomized TAILORx Trial

    Authors: Kathy S. Albain, Robert J. Gray, Della Makower, Amir Faghih, Daniel F. Hayes, Charles E. Geyer, Elizabeth Claire Dees, Matthew P. Goetz, John A. Olson, Tracy Lively, Sunil Badve, Thomas J. Saphner, Lynne I. Wagner, Timothy J. Whelan, Matthew J. Ellis, William C. Wood, Maccon Keane, Henry Gómez, Pavan S. Reddy, Timothy F. Goggins, Ingrid A. Mayer, Adam Brufsky, Deborah Toppmeyer, Virginia Kaklamani, Jeffrey L. Berenberg, Jeffrey S. Abrams, George W. Sledge, Joseph A. Sparano - JNCI Journal of the National Cancer Institute 2020 cited by 114

  23. Patient-Reported Cognitive Impairment Among Women With Early Breast Cancer Randomly Assigned to Endocrine Therapy Alone Versus Chemoendocrine Therapy: Results From TAILORx

    Authors: Lynne I. Wagner, Robert J. Gray, Joseph A. Sparano, Timothy J. Whelan, Sofia F. Garcia, Betina R. Yanez, Amyé Tevaarwerk, Ruth C. Carlos, Kathy S. Albain, John A. Olson, Matthew P. Goetz, Kathleen I. Pritchard, Daniel F. Hayes, Charles E. Geyer, Elizabeth Claire Dees, Worta J. McCaskill-Stevens, Lori M. Minasian, George W. Sledge, David Cella - Journal of Clinical Oncology 2020 cited by 101

  24. Antimicrobial exposure is associated with decreased survival in triple-negative breast cancer

    Authors: Julia D. Ransohoff, Victor Ritter, Natasha Purington, Karen Andrade, Summer S. Han, Mina Liu, Su‐Ying Liang, Esther M. John, Scarlett Lin Gomez, Melinda L. Telli, Lidia Schapira, Haruka Itakura, George W. Sledge, Ami S. Bhatt, Allison W. Kurian - Nature Communications 2023 cited by 36